Role of complement receptor type 2 and endogenous complement in the humoral immune response to conjugates of complement C3d and pneumococcal serotype 14 capsular polysaccharide

Infection and Immunity

Volumn 73, Issue 11, 2005, Pages 7311-7316

  Mitsuyoshi, Joyce K ^a   Hu, Yong ^a   Test, Samuel T ^a  

^a CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; BACTERIAL POLYSACCHARIDE; COBROTOXIN; COMPLEMENT COMPONENT C3D RECEPTOR; COMPLEMENT RECEPTOR; COMPLEMENT RECEPTOR TYPE 2; CONJUGATE VACCINE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN M ANTIBODY; OVALBUMIN; PNEUMOCOCCUS VACCINE; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; COMPLEMENT SYSTEM; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEROTYPE; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODY FORMATION; BACTERIAL CAPSULES; BACTERIAL VACCINES; COMPLEMENT ACTIVATION; COMPLEMENT C3D; FEMALE; IMMUNOCONJUGATES; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOLOGIC MEMORY; MICE; MICE, INBRED BALB C; MICE, INBRED CBA; OVALBUMIN; PROTEIN-TYROSINE KINASES; RECEPTORS, COMPLEMENT 3D;

EID: 27744548927     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.73.11.7311-7316.2005     Document Type: Article

References (23)

1. Dempsey, P. W., M. E. D. Allison, S. Akkaraju, C. C. Goodnow, and D. T. Fearon. 1996. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 271:348-350.
2. Gatto, D., T. Pfister, A. Jegerlehner, S. W. Martin, M. Kopf, and M. F. Bachmann. 2005. Complement receptors regulate differentiation of bone marrow plasma cell precursors expressing transcription factors Blimp-1 and XBP-1. J. Exp. Med. 201:993-1005.
3. Green, T. D., D. C. Montefiori, and T. M. Ross. 2003. Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d. J. Virol. 77:2046-2055.
4. Green, T. D., B. R. Newton, P. A. Rota, Y. Xu, H. L. Robinson, and T. M. Ross. 2002. C3d enhancement of neutralizing antibodies to measles hemagglutinin. Vaccine 20:242-248.
5. Haas, K. M., M. Hasegawa, D. A. Steeber, J. C. Poe, M. D. Zabel, C. B. Bock, D. R. Karp, D. E. Briles, J. H. Weis, and T. F. Tedder. 2002. Complement receptors CD21/35 link innate and protective immunity during Streptococcus pneumoniae infection by regulating IgG3 antibody responses. Immunity 17:713-723.
6. Haas, K. M., F. R. Toapanta, J. A. Oliver, J. C. Poe, J. H. Weis, D. R. Karp, J. F. Bower, T. M. Ross, and T. F. Tedder. 2004. Cutting edge: C3d functions as a molecular adjuvant in the absence of CD21/35 expression. J. Immunol. 172:5833-5837.
7. Hebell, T., J. M. Ahearn, and D. T. Fearon. 1991. Suppression of the immune response by a soluble complement receptor of B lymphocytes. Science 254:102-105.
8. Hellwage, J., T. S. Jokiranta, M. A. Friese, T. U. Wolk, E. Kampen, P. F. Zipfel, and S. Meri. 2002. Complement C3b/C3d and cell surface polyanions are recognized by overlapping binding sites on the most carboxyl-terminal domain of complement factor H. J. Immunol. 169:6935-6944.
9. Henson, S. E., D. Smith, S. A. Boackle, V. M. Holers, and D. R. Karp. 2001. Generation of recombinant human C3dg tetramers for the analysis of CD21 binding and function. J. Immunol. Methods 258:97-109.
10. Lees, A., B. L. Nelson, and J. J. Mond. 1996. Activation of soluble polysaccharides with 1-cyano-4-dimethylammopyridinium tetrafluoroborate for use in protein-polysaccharide conjugate vaccines and immunological reagents. Vaccine 14:190-198.
11. Lou, D., and H. Kohler. 1998. Enhanced molecular mimicry of CEA using photoaffinity crosslinked C3d peptide. Nat. Biotechnol. 16:458-462.
12. Markham, R. B., A. Nicholson-Weller, G. Schiffman, and D. L. Kasper. 1982. The presence of sialic acid on two related bacterial polysaccharides determines the site of the primary immune response and the effect of complement depletion on the response in mice. J. Immunol. 128:2731-2733.
13. Mitchell, J. A., T. D. Green, R. A. Bright, and T. M. Ross. 2003. Induction of heterosubtypic immunity to influenza A virus using a DNA vaccine expressing hemagglutinin-C3d fusion proteins. Vaccine 21:902-914.
14. Mond, J. J., A. Lees, and C. M. Snapper. 1995. T cell-independent antigens type 2. Annu. Rev. Immunol. 13:655-692.
15. Pepys, M. B. 1974. Role of complement in induction of antibody production in vivo. Effect of cobra venom factor and other C3-reactive agents on thymus-dependent and thymus-independent antibody responses. J. Exp. Med. 140:126-145.
16. Pryjma, J., and J. H. Humphrey. 1975. Prolonged C3 depletion by cobra venom factor in thymus-deprived mice and its implication for the role of C3 as an essential second signal for B-cell triggering. Immunology 28:569-576.
17. Quigg, R. J., J. J. Alexander, C. F. Lo, A. Lim, C. He, and V. M. Holers. 1997. Characterization of C3-binding proteins on mouse neutrophils and platelets. J. Immunol. 159:2438-2444.
18. Ross, T. M., Y. Xu, R. A. Bright, and H. L. Robinson. 2000. C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge. Nat. Immunol. 1:127-131.
19. Ross, T. M., Y. Xu, T. D. Green, D. C. Montefiori, and H. L. Robinson. 2001. Enhanced avidity maturation of antibody to human immunodeficiency virus envelope: DNA vaccination with gp120-C3d fusion proteins. AIDS Res. Hum. Retrovir. 17:829-835.
20. Test, S. T., J. Mitsuyoshi, C. C. Connolly, and A. H. Lucas. 2001. Increased immunogenicity and induction of class switching by conjugation of complement C3d to pneumococcal serotype 14 capsular polysaccharide. Infect. Immun. 69:3031-3040.
21. Test, S. T., J. K. Mitsuyoshi, and Y. Hu. 2005. Depletion of complement has distinct effects on the primary and secondary antibody responses to a conjugate of pneumococcal serotype 14 capsular polysaccharide and a T-cell-dependent protein carrier. Infect. Immun. 73:277-286.
22. Verheul, A. F. M., A. A. Versteeg, M. J. De Reuver, M. Jansze, and H. Snippe. 1989. Modulation of the immune response to pneumococcal type 14 capsular polysaccharide-protein conjugates by the adjuvant Quil A depends on the properties of the conjugates. Infect. Immun. 57:1078-1083.
23. Watanabe, I., T. M. Ross, S. Tamura, T. Ichinohe, S. Ito, H. Takahashi, H. Sawa, J. Chiba, T. Kurata, T. Sata, and H. Hasegawa. 2003. Protection against influenza virus infection by intranasal administration of C3d-fused hemagglutinin. Vaccine 21:4532-4538.